TMR observes that the global transdermal scopolamine market is experiencing the high competition and consolidation due to presence of strong players. Some of the key players operating in the global transdermal scopolamine market includes Baxter International Inc., Novartis AG, GlaxoSmithKline Plc, Caleb Pharmaceuticals Inc, Perrigo Co. Plc, and Myungmoon Pharma Co. Ltd. Among them, Novartis AG accounted for nearly 41.0% of the overall revenue in 2016 of the global transdermal scopolamine market. GlaxoSmithKline Plc and Baxter International Inc., accounted for 49.0% of shares together in the same year. The presence of small companies in the market are intensifying competition and international players are adopting the strategies like acquiring small or local companies to strengthen their presence in region and for business expansion.